Formulary Tiers Route the Same Diabetes Drug to Two Prices
A formulary is a list of drugs a plan will cover, and where a drug sits on that list decides what the patient pays. The same metformin tablet, made by the same manufacturer, can carry a $4 copay at one counter and a $40 bill at another. Tier placement, not the molecule, sets the price.
Same Pill, Two Price Tags
Formularies divide drugs into tiers. Tier 1 usually means generic with a low flat copay. Tier 3 or higher often means a percentage coinsurance rather than a fixed dollar amount. That percentage applies to a list price that can be several times what the pharmacy actually pays, so the patient's share floats upward with the sticker price.
Metformin is a useful example because it is old, generic, and cheap to make. On a Tier 1 plan a month's supply might cost a few dollars. Move the same tablet to a non-preferred tier and the coinsurance can push the counter price into the tens of dollars. The pharmacy's acquisition cost barely changes. The plan's cost-sharing formula does.
Pharmacy benefit managers negotiate rebates with manufacturers in exchange for preferred placement. Those rebates flow back to the plan, not to the patient at the counter. A patient paying coinsurance on a non-preferred drug often pays a percentage of a list price that the rebate has already discounted behind the scenes. The gap between list and net is where the patient's bill lives.
The arithmetic is not subtle. If a plan sets coinsurance at 30 percent and the list price for a 30-day supply is $100, the patient pays $30. If the pharmacy's acquisition cost is $10, the plan's net cost after a rebate might be $6, and the patient's $30 covers the plan's share and then some. The patient's exposure is to the list price, not to the true cost. For a drug that costs pennies to manufacture, that spread is the whole story.
Who Decides the Tier
Tier assignment is made by committees inside pharmacy benefit managers, the third-party administrators that run prescription drug programs for commercial plans, Medicare Part D, and state employee plans. CVS Caremark, the PBM subsidiary of CVS Health, and Evernorth, which houses Cigna's health services arm, are among the largest gatekeepers. Their preferred drug lists decide which products get the low copay.
Rebate deals drive many of those decisions. A manufacturer that offers a larger rebate can secure preferred status, pushing a competitor to a higher tier even when the two drugs are therapeutically interchangeable. For a generic like metformin, where several manufacturers compete, the tier can shift from plan to plan and year to year as contracts renew.
Prior authorization adds a second layer. EviCore by Evernorth, owned by Cigna and based in Bluffton, South Carolina, reviews prior authorizations for specialized procedures and medications on behalf of more than a hundred insurers and Medicaid programs. It is the largest such reviewer in the United States. When a drug is non-preferred, a request for coverage often routes through a review like this before the pharmacy will fill it.
The tiering logic extends beyond generics. Brand-name drugs for diabetes, such as GLP-1 receptor agonists, often sit on the highest tiers, and their coinsurance can run into hundreds of dollars per month. A patient with type 2 diabetes may find that the older, cheaper metformin is preferred while the newer injectable is not, even though both are used for the same condition. The clinical choice between them involves cardiovascular and renal benefits, weight effects, and tolerability, but the formulary often reduces that choice to a binary: preferred or not.
The Prior Authorization Wall
Non-preferred status usually means the pharmacy cannot fill the prescription without an approved prior authorization. That sets off paperwork: the prescriber's office submits clinical justification, the reviewer applies criteria, and the patient waits. Approval rates vary widely by plan and by state, and a denial can be appealed, but the appeal takes time the patient may not have.
The practical effect is a nudge. A patient who needs the drug today may pay the higher tier price rather than wait days for a review. That is not a formal policy of denying care. It is a friction that shifts cost onto the person least able to absorb it, and it works because the alternative is going without.
For a drug like metformin, the prior authorization requirement is often waived because the drug is cheap and the plan would rather pay a small amount than process paperwork. But for newer agents, the requirement is routine. A patient who has tried metformin and cannot tolerate it may need a DPP-4 inhibitor or an SGLT2 inhibitor. Those drugs are frequently non-preferred, and the prior authorization may require documentation of metformin failure, which means the patient must first try a drug that made them sick before the plan will cover the alternative. That is a clinical decision made by a formulary committee, not by the prescriber.
A related piece on this site, on how depression care differs by clinic wealth, makes a similar point about how administrative design sorts patients by setting rather than by need. The mechanism differs, the sorting does not.
Safety-Net Clinics Lose Leverage
Large health systems employ pharmacists who sit on formulary committees and negotiate directly with PBMs. A small community health center does not. It writes prescriptions into whatever formulary its patients' plans use, with no seat at the table and no staff dedicated to tracking tier changes between plan years.
Medicaid managed care adds another layer of variation. Each state runs its own program, and within a state different managed care organizations can place the same drug on different tiers. A patient who moves between plans, or whose plan changes formulary mid-year, can see the price of an unchanged prescription jump without any change in their condition.
Uninsured patients pay cash, and cash prices at safety-net pharmacies are not always lower than the insured copay on a preferred tier. A patient without coverage may pay more for the same metformin than a neighbor with a Tier 1 plan, because the insured price reflects a negotiated rate the cash customer never sees. A piece on this site about burnout funding arriving after staff have left touches the same pattern of resources missing the moment they were needed.
The safety-net clinic's disadvantage compounds over time. Without staff to monitor formulary changes, the clinic may not know that a drug moved to a non-preferred tier until patients start complaining about bills. By then, the prior authorization backlog has already built up, and the clinic's limited nursing time is consumed by paperwork rather than patient care. A large system can absorb that shock by reassigning pharmacists; a small clinic cannot.
What a GP Can Actually Do
Check the formulary before writing the script, not after the patient reports a surprising bill. Most plans publish tier lists online, and the prescriber's e-prescribing system often flags non-preferred status at the point of order. A two-minute check can avoid a week of prior authorization paperwork.
When a drug is non-preferred, document medical necessity in the note the same day. Reviewers want the diagnosis, the prior therapies tried, and the reason the preferred alternative is unsuitable. A specific clinical rationale moves faster than a generic request, and it gives the patient something to cite if the first review denies.
Ask the pharmacy for the cash price alongside the insurance price. For a cheap generic, the cash price can be lower than the coinsurance on a non-preferred tier, and the pharmacist can run both without filling either. Patient assistance programs and manufacturer coupons help in some cases, though coupons often exclude federally funded plans.
Appeal the tier placement when the clinical case is strong. Tier exceptions exist, and a letter from the prescriber citing the patient's history and the failed alternatives is the usual basis. It is slow, and it does not always work, but it is the lever available when the formulary committee is not.
Finally, keep a list of the formularies that cover your most common prescriptions. It takes an hour to build and saves that hour many times over. When a patient's plan changes, you can check the list before the patient reaches the counter. That small step does not fix the system, but it keeps the cost from landing on the patient by default.
This article is informational and does not constitute personalised medical, legal, or financial advice. Coverage rules and drug prices vary by plan, state, and year; patients should confirm details with their prescriber, pharmacist, or insurer.
